SGR-2921 was being evaluated in an early-stage study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
Schrödinger, Inc. (SDGR) announced on Thursday that it is discontinuing the clinical development program for SGR-2921, which was being evaluated in an early-stage study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
The decision was made in light of two treatment-related deaths in the early-stage study, the company said. Schrödinger opined that developing the drug as a combination therapy would be difficult to pursue despite evidence of activity as a singular drug.
Margaret Dugan, chief medical officer at Schrödinger, said, “Patient safety is our first priority, and in light of two treatment-related deaths in the Phase 1 dose-escalation study, we have made the decision to discontinue further development of SGR-2921. While disappointing given the early clinical activity observed, we believe this is the right decision for patients.”
Get updates to this developing story <directly on Stocktwits.<